

## **StemRIM Announces Completion of Patient Enrollment in the Phase 1/2 Investigator-Initiated Clinical Trial of Redasemtide for Patients with Ischemic Cardiomyopathy**

**Osaka, Japan, April 15, 2026** – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; “StemRIM” or “Company”) announces that StemRIM have received notification from Osaka University Hospital, that patient enrollment has been completed in the Phase 1/2 investigator-initiated clinical trial for Ischemic Cardiomyopathy (the “Trial”) of Redasemtide, "Regeneration-Inducing Medicine™" candidate that has already been licensed out by the Company to Shionogi & Co., Ltd. (Head Office: Kita-ku, Osaka; Representative Director, Chairman of the Board and CEO: Isao Teshirogi).

The Trial was conducted as an investigator-initiated clinical trial at a total of 5 institutions, led by Osaka University Hospital. The Trial enrolled 14 patients with ischemic cardiomyopathy who underwent coronary artery bypass grafting, and Redasemtide or placebo was administered for five days. The primary objective of the Trial is to evaluate the safety and tolerability of Redasemtide. For efficacy assessment, various cardiac function tests are planned to be conducted 52 weeks after administration as secondary endpoints.

Although the initial plan was to enroll 20 patients (10 patients in the Redasemtide group and 10 patients in the placebo group), patient enrollment was completed with 14 patients based on the determination that this number of cases would be sufficient to provide a certain level of evaluation for the primary objective of safety and tolerability, taking into account the overall status of the Trial.

Details of the Trial are available on the Japan Registry of Clinical Trials (jRCT), a clinical research database (Clinical Research Submission and Publication System).

(Reference)

<https://jrct.mhlw.go.jp/latest-detail/jRCT2051240065>

At this time, there is no impact on the Company’s consolidated financial results for the fiscal year ending July 2026.

### **About StemRIM Inc.**

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities,

promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with ectomesenchymal stem cells is promising.

**Inquiries:**

StemRIM Inc.

Management & Administrator Dept.

E-Mail: [stemrim-ir@stemrim.com](mailto:stemrim-ir@stemrim.com)

X: [@StemRIM\\_Inc](#)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)